# US 2023/0144122 A1 · Pyridone derivative crystal form and preparation method and application therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0144122 A1
- Document ID: US20230144122A1
- Status: Published application
- Kind: A1
- Application number: 17/595,013
- Filed: 2019-11-05
- Published: 2023-05-11
- Earliest claimed: 2019-05-08
- Assignees: Jiangxi Caishi Pharmaceutical Technology Co., Ltd.
- Applicants: Jiangxi Caishi Pharmaceutical Technology Co., Ltd.
- Inventors: Qing SHAO; Libin GAN; Li CHEN
- Web page: https://patentgrep.com/patent/US20230144122A1

## CPC

- C07D 498/14: Ortho-condensed systems
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 31/16: for influenza or rhinoviruses
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided are crystals of (((R)-12′-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6′,8′-dioxo-6′,8′,12′,12a′-tetrahydro-1′H,4′H-spiro[cyclopropane-1,3′-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin]-7′-yl)oxy)methyl methyl carbonate, i.e. compound of Formula (1) or a solvate thereof and a preparation method therefor, the crystals comprising crystal form A, crystal form B, crystal form C, crystal form D, crystal form E, crystal form F, and single crystal. The crystal of the compound of Formula (1) or a solvate thereof can be individually used for clinical treatment or in combination with other anti-influenza drugs such as neuraminidase inhibitors, nucleoside drugs, or PB2 inhibitors, being capable of clinically curing influenza patients quickly, and having very good activity and good bioavailability compared to existing pyridone derivatives. In addition, the stability, hygroscopicity, and storability of the crystals meet the requirements for pharmaceutical use.

## Claims

### Claim 1

A crystal of a compound of Formula (1) or a solvate thereof:

### Claim 2 (depends on 1)

The crystal as claimed in claim 1, is characterized in that, the crystal is in crystal form A of the compound of formula (1), which has an X-ray powder diffraction pattern with characteristic peaks at 2θ of 3.10°±0.2°, 8.74°±0.2°, 15.44°±0.2° and 21.91°±0.2°.

### Claim 3 (depends on 2)

The crystal as claimed in claim 2, is characterized in that, the X-ray powder diffraction pattern of the crystal form A of the compound of formula (1) further has one or more characteristic peaks at 2θ of 13.08°±0.2°, 26.35°±0.2°, and 30.83°±0.2°.

### Claim 4 (depends on 2, 3)

The crystal as claimed in claim 2 or 3, is characterized in that, a spectrum of the crystal form A of the compound of formula (1) determined by thermogravimetric analysis shows that it loses 1.8±0.2% in weight when heated to 150±2° C.; and/or, a spectrum of the crystal form A of the compound of formula (1) determined by differential scanning calorimetry shows one endothermic peak, indicating that a melting point onset temperature of the crystal form A is 230.5±2° C.

### Claim 5 (depends on 2, 3)

The crystal as claimed in claim 2 or 3, is characterized in that, the crystal form A of the compound of formula (1) is an anhydrous crystal form.

### Claim 6 (depends on 1)

The crystal as claimed in claim 1, is characterized in that, the crystal is in crystal form B of the compound of formula (1), which has an X-ray powder diffraction pattern with characteristic peaks at 2θ of 8.42°±0.2°, 14.27°±0.2°, 16.04°±0.2° and 25.41°±0.2°.

### Claim 7 (depends on 6)

The crystal as claimed in claim 6, is characterized in that, the X-ray powder diffraction pattern of the crystal form B of the compound of formula (1) further has one or two characteristic peaks at 2θ of 10.75°±0.2° and 16.87°±0.2°.

### Claim 8 (depends on 6, 7)

The crystal as claimed in claim 6 or 7, is characterized in that, the X-ray powder diffraction pattern of the crystal form B of the compound of formula (1) further has one or more characteristic peaks at 2θ of 18.21°±0.2°, 18.78°±0.2°, 19.26°±0.2°, 19.60°±0.2°, 20.40°±0.2°, 21.39°±0.2°, 21.66°±0.2°, 23.38°±0.2°, 27.32°±0.2°, 29.17°±0.2% and 34.08°±0.2°.

### Claim 9 (depends on 6, 7)

The crystal as claimed in claim 6 or 7, is characterized in that, a spectrum of the crystal form B of the compound of formula (1) determined by thermogravimetric analysis shows that it loses 2.2±0.2% in weight when heated to 150±2° C.; and/or, a spectrum of the crystal form B of the compound of formula (1) determined by differential scanning calorimetry shows two endothermic peaks, and onset temperatures of the two endothermic peaks are 208.5±2° C. and 233.8±2° C., respectively.

### Claim 10 (depends on 6, 7)

The crystal as claimed in claim 6 or 7, is characterized in that, the crystal form B of the compound of formula (1) is an anhydrous crystal form.

### Claim 11 (depends on 1)

The crystal as claimed in claim 1, is characterized in that, the crystal is in crystal form C of the compound of formula (1), which has an X-ray powder diffraction pattern with characteristic peaks at 2θ of 7.73°±0.2°, 17.13°±0.2°, 20.08°±0.2° and 21.74°±0.2°.

### Claim 12 (depends on 11)

The crystal as claimed in claim 11, is characterized in that, the X-ray powder diffraction pattern of the crystal form C of the compound of formula (1) further has one or more characteristic peaks at 2θ of 13.13°±0.2°, 13.65°±0.2°, 20.98°±0.2°, and 23.22°±0.2°.

### Claim 13 (depends on 11, 12)

The crystal as claimed in claim 11 or 12, is characterized in that, the X-ray powder diffraction pattern of the crystal form C of the compound of formula (1) further has one or more characteristic peaks at 2θ of 12.51°±0.2°, 14.76°±0.2°, 15.21°±0.2°, 18.39°±0.2°, and 24.13°±0.2°.

### Claim 14 (depends on 11, 12)

The crystal as claimed in claim 11 or 12, is characterized in that, a spectrum of the crystal form C of the compound of formula (1) determined by thermogravimetric analysis shows that it loses 12.05±0.2% in weight when heated to 150±2° C.; and/or, a spectrum of the crystal form C of the compound of formula (1) determined by differential scanning calorimetry shows two endothermic peaks, and onset temperatures of the two endothermic peaks are 86.8±2° C. and 233.9±2° C., respectively.

### Claim 15 (depends on 11, 12)

The crystal as claimed in claim 11 or 12, is characterized in that, the crystal form C of the compound of formula (1) is a tetrahydrofuran solvate of the compound of formula (1).

### Claim 16 (depends on 1)

The crystal as claimed in claim 1, is characterized in that, the crystal is in crystal form D of the compound of formula (1), which has an X-ray powder diffraction pattern with characteristic peaks at 2θ of 7.94°±0.2°, 22.16°±0.2°, and 28.03°±0.2°.

### Claim 17 (depends on 16)

The crystal as claimed in claim 16, is characterized in that, the X-ray powder diffraction pattern of the crystal form D of the compound of formula (1) further has one or more characteristic peaks at 2θ of 15.09°±0.2°, 15.50°±0.2°, 19.63°±0.2°, 23.56°±0.2% and 25.86°±0.2°.

### Claim 18 (depends on 16, 17)

The crystal as claimed in claim 16 or 17, is characterized in that, a spectrum of the crystal form D of the compound of formula (1) determined by thermogravimetric analysis shows that it loses 7.5±0.2% in weight when heated to 150±2° C.; and/or, a spectrum of the crystal form D of the compound of formula (1) determined by differential scanning calorimetry shows two endothermic peaks, and onset temperatures of the two endothermic peaks are 113.2±2° C. and 230.6±2° C., respectively.

### Claim 19 (depends on 16, 17)

The crystal as claimed in claim 16 or 17, is characterized in that, the crystal form D of the compound of formula (1) is a N-methyl-2-pyrrolidone solvate of the compound of formula (1).

### Claim 20 (depends on 1)

The crystal as claimed in claim 1, is characterized in that, the crystal is in crystal form E of the compound of formula (1), which has an X-ray powder diffraction pattern with characteristic peaks at 2θ of 8.01°±0.2°, 8.78°±0.2°, and 26.33°±02°.

### Claim 21 (depends on 20)

The crystal as claimed in claim 20, is characterized in that, the X-ray powder diffraction pattern of the crystal form E of the compound of formula (1) further has one or more characteristic peaks at 2θ of 4.44°±0.2°, 17.56°±0.2°, 21.95°±0.2°, and 22.25°±0.2°.

### Claim 22 (depends on 20, 21)

The crystal as claimed in claim 20 or 21, is characterized in that, the X-ray powder diffraction pattern of the crystal form E of the compound of formula (1) further has one or more characteristic peaks at 2θ of 5.87°±0.2°, 19.64°±0.2°, 28.15°±0.2°, 29.07°±0.2% and 30.86°±0.2°.

### Claim 23 (depends on 1)

The crystal as claimed in claim 1, is characterized in that, the crystal is in crystal form F of the compound of formula (1), which has an X-ray powder diffraction pattern with characteristic peaks at 2θ of 5.77°±0.2% 8.69°±0.2°, 17.48°±0.2° and 22.84°±0.2°.

### Claim 24 (depends on 23)

The crystal as claimed in claim 23, is characterized in that, the X-ray powder diffraction pattern of the crystal form F of the compound of formula (1) further has one or two characteristic peaks at 2θ of 11.61°±0.2° and 19.47°±0.2°.

### Claim 25 (depends on 23, 24)

The crystal as claimed in claim 23 or 24, is characterized in that, the X-ray powder diffraction pattern of the crystal form F of the compound of formula (1) further has one or more characteristic peaks at 2θ of 11.98°±0.2% 13.84°±0.2% 14.30°±0.2% 18.33°±0.2% and 18.95°±0.2°.

### Claim 26 (depends on 23, 24)

The crystal as claimed in claim 23 or 24, is characterized in that, a spectrum of the crystal form F of the compound of formula (1) determined by thermogravimetric analysis shows that it loses 1.16±0.2% in weight when heated to 150±2° C.; and/or, a spectrum of the crystal form F of the compound of formula (1) determined by differential scanning calorimetry shows an endothermic peak, and an onset temperature of the endothermic peak is 231.1±2° C.

### Claim 27 (depends on 23, 24)

The crystal as claimed in claim 23 or 24, is characterized in that, the crystal form F of the compound of formula (1) is an anhydrous crystal form.

### Claim 28 (depends on 1, 23)

The crystal as claimed in claim 1 or 23, is characterized in that, the crystal is in a single crystal form, which belongs to orthorhombic crystal system, with space group P212121, and unit-cell parameters are: a=11.7±0.2 Å, b=19.6±0.2 Å, c=23.4±0.2 Å, α=90°±0.2°, β=90°±0.2°, γ=90°±0.2°.

### Claim 29 (depends on 28)

The crystal as claimed in claim 28, is characterized in that, the unit-cell parameters are: a=11.65-11.75 Å, b=19.50-19.60 Å, c=23.33-23.43 Å, α=89.9-90.1°, β=89.9-90.1°, γ=89.9-90.1°.

### Claim 30 (depends on 28, 29)

The crystal as claimed in claim 28 or 29, is characterized in that, a method for preparing the single crystal comprises: dissolving the compound of formula (1) in an alcohol solvent, filtering, volatilizing the solvent in a filtrate at room temperature to precipitate crystals, collecting the resulting crystals by filtration, and drying at room temperature to obtain.

### Claim 31 (depends on 1, 2, 3, 4, 5)

A preparation method for the crystal as claimed in any one of claims 1-5, is characterized in that, the preparation method comprises:
1) adding the compound of formula (1) to one of or a mixture of more of an ester solvent, an alcohol solvent, and a ketone solvent to dissolve, then mixing with a hydrocarbon solvent, crystallizing, filtering, and drying to give a crystal form A of the compound of formula (1); or
2) adding the compound of formula (1) to a ketone solvent, volatilizing the solvent at room temperature to obtain a solid, and drying the resulting solid to give a crystal form A of the compound of formula (1); or
3) adding the compound of formula (1) to an ether solvent, stirring at room temperature, filtering to obtain a solid, and drying the resulting solid to give a crystal form A of the compound of formula (1); or
4) adding the compound of formula (1) to water, stirring at 45-55° C., filtering to obtain a solid, and drying the resulting solid to give a crystal form A of the compound of formula (1); or
5) adding the compound of formula (1) to a mixture solvent of a hydrocarbon solvent and an ether solvent, stirring at a set temperature for 1 to 3 h, then heating up or cooling at a rate of 0.1±0.05° C./min to circulate the temperature of the system between the set temperature and 5° C. for several times, and finally stirring at 3-7° C., filtering to obtain a solid, and drying the resulting solid to give a crystal form A of the compound of formula (1), the set temperature is 45 to 55° C.

### Claim 32 (depends on 1, 6, 7, 8, 9, 10)

A preparation method for the crystal as claimed in any one of claims 1 and 6-10, is characterized in that, the preparation method comprises:
1) adding the compound of formula (1) to an alcohol solvent or a ketone solvent or a mixture thereof to dissolve, mixing with water, crystallizing, filtering to obtain a solid, and drying the resulting solid to give a crystal form B of the compound of formula (1); or
2) adding the compound of formula (1) to a halohydrocarbon solvent, volatilizing the solvent at room temperature to obtain a solid, and drying the resulting solid to give a crystal form B of the compound of formula (1); or
3) adding the compound of formula (1) to a hydrocarbon solvent, stirring at room temperature, filtering to obtain a solid, and drying the resulting solid to give a crystal form B of the compound of formula (1); or
4) adding the compound of formula (1) to 2-methyltetrahydrofuran, stirring at a first set temperature, filtering and collecting a supernatant, and cooling the supernatant from a first set temperature to a second set temperature at a rate of 0.1±0.05° C./min and maintaining at the second set temperature, collecting a precipitated solid, and drying the resulting solid to give a crystal form B of the compound of formula (1), the first set temperature is 45 to 55° C., and the second set temperature is 0 to 10° C.

### Claim 33 (depends on 1, 11, 12, 13, 14, 15)

A preparation method for the crystal as claimed in any one of claims 1 and 11-15, is characterized in that, the method comprises: adding the compound of formula (1) to a mixture system of tetrahydrofuran and a hydrocarbon solvent to form a turbid solution, stirring at a first set temperature, filtering and collecting a supernatant, and cooling the supernatant from a first set temperature to a second set temperature at a rate of 0.1±0.05° C./min and maintaining at the second set temperature, collecting a precipitated solid, and drying the resulting solid to give a crystal form C of the compound of formula (1), the first set temperature is 45 to 55° C., and the second set temperature is 0 to 10° C.

### Claim 34 (depends on 1, 16, 17, 18, 19)

A preparation method for the crystal as claimed in any one of claims 1 and 16-19, is characterized in that, the method comprises: adding the compound of formula (1) to a mixture of N-methyl-2-pyrrolidone and water to form a turbid solution, stirring at 45-55° C., filtering to obtain a solid, and drying the resulting solid to give a crystal form D of the compound of formula (1).

### Claim 35 (depends on 1, 20, 21, 22)

A preparation method for the crystal as claimed in any one of claims 1 and 20-22, is characterized in that, the method comprises: dissolving the compound of formula (1) in N,N-dimethylacetamide, obtaining a solid by gas-liquid diffusion in an atmosphere of water or an alcohol solvent, and filtering to give a crystal form E of the compound of formula (1).

### Claim 36 (depends on 1, 23, 24, 25, 26, 27)

A preparation method for the crystal as claimed in any one of claims 1 and 23-27, is characterized in that, the method comprises: adding the compound of formula (1) to an ester solvent or an alcohol solvent or a mixture thereof to form a turbid solution, stirring at 0-10° C., filtering to obtain a solid, and drying the resulting solid to give a crystal form F of the compound of formula (1).

### Claim 37 (depends on 36)

The preparation method as claimed in claim 36, is characterized in that, the ester solvent is ethyl acetate; and/or, the alcohol solvent is methanol and/or ethanol; and/or, stirring time is 2-4 h.

### Claim 38 (depends on 36, 37)

The preparation method as claimed in claim 36 or 37, is characterized in that, before stirring the turbid solution at 0-10° C., heating the turbid solution to 30-60° C., and stirring at this temperature for more than 5 min.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A pharmaceutical composition containing the crystal as claimed in any one of claims 1-30 and a pharmaceutically acceptable carrier.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

Use of the crystal as claimed in any one of claims 1-30 in the preparation of anti-influenza virus drugs.
